Pentacel vaccine consists of Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus (DTaP-IPV) component and an ActHIB® vaccine component
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b.
Pentacel is administered as an intramuscular injection.
Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday).
June 23, 2008 - Sanofi Pasteur, announced that the U.S. Food and Drug Administration (FDA) has licensed Pentacel® vaccine that is approved for use in infants and children 6 weeks through 4 years of age (prior to the fifth birthday).
Pentacel® vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.